# OnCo record idea-same-fragment-methylation-and-mutation (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-same-fragment-methylation-and-mutation/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-same-fragment-methylation-and-mutation" ;
  schema:name "Read methylation and mutation on the same cell-free DNA fragment to tell what kind of cancer is left"@en ;
  schema:alternateName "Same-fragment methylation and mutation"@en, "Phenotype from residual ctDNA molecules"@en ;
  schema:description "A proposal, untested: when a blood test finds a tumour fragment after treatment, also read the chemical marks on that same piece of DNA, which might show whether the cell it came from was making the oestrogen receptor or TROP2."@en ;
  schema:url <https://onco.cc/ideas/idea-same-fragment-methylation-and-mutation/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://doi.org/10.1038/s41698-026-01523-w>, <https://doi.org/10.1038/s41586-023-05776-4>, <https://doi.org/10.1038/s41587-021-00900-z> ;
  onco:tag "proposal" ;
  onco:related <https://onco.cc/ideas/idea-bio1-methylation-clone-tracking/>, <https://onco.cc/ideas/idea-trop2-pet-selection/> ;
  onco:cancers <https://onco.cc/cancers/breast-cancer/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/tnbc/> ;
  onco:technologies <https://onco.cc/technologies/saferseqs/>, <https://onco.cc/technologies/eclipse-subclone-ctdna/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/meter-methylome-subtyping/>, <https://onco.cc/technologies/griffin-nucleosome-profiling/> ;
  onco:targets <https://onco.cc/targets/trop2/>, <https://onco.cc/targets/estrogen-receptor/> ;
  onco:terms <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/cfdna/>, <https://onco.cc/terms/mrd/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-subclone-attribution-residual-disease/>, <https://onco.cc/bottlenecks/b-tumor-heterogeneity/>, <https://onco.cc/bottlenecks/b-dormancy-mrd/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-notini-trop2-pan-cancer-multiomic-npj-precis-oncol-2026/>, <https://onco.cc/key-papers/paper-abbosh-tracerx-ctdna-relapse-nature-2023/>, <https://onco.cc/key-papers/paper-cohen-saferseqs-nat-biotechnol-2021/>, <https://onco.cc/key-papers/paper-coates-sacituzumab-resistance-tacstd2-cancer-discov-2021/>, <https://onco.cc/key-papers/paper-paoli-meter-methylome-subtyping-genome-med-2026/>, <https://onco.cc/key-papers/paper-doebley-griffin-nucleosome-profiling-nat-commun-2022/> .
